Joe Cantanzaro

“Maybe first question from me, I know maybe patient numbers get a little bit small, but wondering if you could speak to the efficacy you're observing in the subgroup of patients with prior JAK inhibitor therapy versus those who are JAK-naive, and would expectations moving forward be to continue to allow patients with…”